| Literature DB >> 17268110 |
Yasushi Igarashi1, Erika Yanagisawa, Toshihiro Ohshima, Shuichi Takeda, Masaki Aburada, Ken-ichi Miyamoto.
Abstract
A series of carbamates of the phenolic compound 1 were prepared and evaluated in vivo as its prodrug. Each carbamate was orally administered to rats, and plasma concentrations of the parent compound 1 were measured with the passage of time. We judged which carbamate was suitable for the prodrug of 1 from both the AUC value of 1 and absence of the carbamate in plasma. The AUC value of 1 after oral administration of 2b was approximately 40-fold higher than that for an administration of 1, and the bioconversion from 2b to 1 was excellent. As a whole, di-substituted carbamates resulted in higher plasma concentrations of 1 than did mono-substituted ones. However di-substituted carbamates were almost always detected in plasma. As a result, we found that the ethycarbamoyl derivative 2b demonstrates the best prodrug property in this series.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17268110 DOI: 10.1248/cpb.55.328
Source DB: PubMed Journal: Chem Pharm Bull (Tokyo) ISSN: 0009-2363 Impact factor: 1.645